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Abstract: Osteosarcoma, the most frequent malignant primary bone tumor in pediatric patients is characterized by 
osteolysis promoting tumor growth. Lung metastasis is the major bad prognosis factor of this disease. Zoledronic 
Acid (ZA), a potent inhibitor of bone resorption is currently evaluated in phase III randomized studies in Europe for 
the treatment of osteosarcoma and Ewing sarcoma. The beneficial effect of the liposomal form of Muramyl-TriPep-
tide-Phosphatidyl Ethanolamine (L-mifamurtide, MEPACT®), an activator of macrophage populations has been dem-
onstrated to eradicate lung metastatic foci in osteosarcoma. The objective of this study was to evaluate the potential 
therapeutic benefit and the safety of the ZA and L-mifamurtide combination in preclinical models of osteosarcoma, 
as a prerequisite before translation to patients. The effects of ZA (100 µg/kg) and L-mifamurtide (1 mg/kg) were 
investigated in vivo in xenogeneic and syngeneic mice models of osteosarcoma, at clinical (tumor proliferation, 
spontaneous lung metastases development), radiological (bone microarchitecture by microCT analysis), biological 
and histological levels. No interference between the two drugs could be observed on ZA-induced bone protection 
and on L-mifamurtide-induced inhibition of lung metastasis development. Unexpectedly, ZA and L-mifamurtide asso-
ciation induced an additional and in some cases synergistic inhibition of primary tumor progression. L-mifamurtide 
has no effect on tumor proliferation in vitro or in vivo, and macrophage population was not affected at the tumor 
site whatever the treatment. This study evidenced for the first time a significant inhibition of primary osteosarcoma 
progression when both drugs are combined. This result constitutes a first proof-of-principle for clinical application 
in osteosarcoma patients.
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Introduction
Osteosarcoma is the most frequent malignant 
primary bone tumor in young people with 
around 1000 new cases per year in Europe [1, 
2]. It arises mainly in adolescents and young 
adults (median age 18 years), with a preferen-
tial location in the metaphysis of long bones. 
The standard treatment of osteosarcoma con-
sists in multi-drug chemotherapy as neo-adju-
vant and adjuvant settings associated with sur-
gical local control [3, 4]. Despite recent ad- 
vances in limb-salvage surgery and poly-che-
motherapy combinations, event-free survival 
and overall survival have only slightly improv- 
ed during the last decades remaining around 
65-70% at 5 years for localized forms and only 
25% for patients who present pulmonary metas-
tases at diagnosis. The current drug regimens 
used for osteosarcoma pediatric patients as- 
sociate MTX-VP-IFO (High dose methotrexate, 
Vincristin, platinium and ifosfamide) or API-AI 
for adults (adriamycin-platinium-ifosfamide). 
However, patients who do not respond to che-
motherapy have an overall survival of only 
20-25% at 5 years [5, 6]. Therefore, new thera-
peutic targets are urgently needed for these 
patients at high risk.
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Recently, L-mifamurtide (Liposomal-Muramyl 
TriPeptide-PhosphatidylEthanolamine: L-MTP-
PE) has been proposed as adjuvant therapy 
for osteosarcoma patients in the United States. 
It is a synthetic analog of the muramyl dipep-
tide (MDP), resulting from the covalent addi- 
tion of alanin and dipalmitoylphosphatidyl 
ethanolamine to MDP, a peptidoglycan found in 
bacterial cell wall [7]. L-mifamurtide acts as 
a nonspecific immunomodulator by activating 
macrophages and monocytes related to the 
upregulation of tumoricidal activity and secre-
tion of pro-inflammatory cytokines including 
tumor necrosis factor (TNF)-a, interleukin (IL)-1, 
IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin 
E2 (PGE2) and PGD2 [8-10]. The lipid composi-
tion of mifamurtide has been developed to tar-
get delivery of the drug selectively to mono-
cytes and macrophages in liver, spleen and 
lungs [7, 11, 12]. It also facilitates signaling via 
phosphatidyl serine recognition by macroph- 
ages [13]. Moreover, the liposomal formulation 
can improve the safety profile of several drugs 
by modifying parent drug or solubilization agent 
toxicity [14]. In 2011, Buddingh and al. report-
ed that tumor-associated-macrophages (TAMs) 
are associated with good prognosis in high 
grade osteosarcoma [15]. In contrast to most 
other tumor types, TAMs are associated with 
reduced metastasis and improved survival for 
those patients. A phase III randomized clinical 
trial was conducted by the Children‘s oncology 
group (COG) from 1993 to 1997 [16]. Significant 
improvement in EFS and overall survival were 
observed in patients randomized to receive 
L-mifamurtide [7, 17, 18]. In the European Un- 
ion, except in France, L-mifamurtide is indicat-
ed in patients aged between 2 and 30 years 
with high-grade, resectable, nonmetastatic os- 
teosarcoma after the complete surgical wide 
resection.
In France, OS2006 is the current clinical proto-
col for pediatric and adult osteosarcoma pa- 
tients, a phase III randomized study associat- 
ing Zometa® (ZA, zoledronic acid) with con- 
ventional poly-chemotherapy and surgery. This 
protocol is based on preclinical studies from 
our group demonstrating the advantage of 
combination of antitumor therapy with drugs 
that target the bone microenvironment [19, 
20]. Indeed, interactions between tumor cells 
and bone cells are closely regulated in the so 
called “vicious cycle” as initially proposed by 
Paget [21]. Tumor cells proliferating in bone 
produce osteoclast activating factors such 
as PTH-rP, IL-11, IL-6 or the main regulator 
of osteoclast function: Receptor Activator of 
NF-кB Ligand (RANKL). When activated, osteo-
clasts are able to degrade bone, and allow the 
release of growth factors stored in the bone 
matrix such as Transforming Growth Factor-b, 
Insulin-like Growth Factor-1, Fibroblast Growth 
Factor… that in turn activate tumor cell prolif-
eration [22].
The third generation nitrogen-containing Bis- 
phosphonates (N-BPs) and among them zole-
dronic acid are potent inhibitors of osteoclast 
functions resulting in inhibition of bone resorp-
tion [23, 24]. In addition, N-BPs slow down 
tumor growth in bone, both indirectly by inhibit-
ing osteoclast activation and directly by inhibi-
tion of tumor cell proliferation, angiogenesis, 
migration and activation of γδT lymphocytes 
[25, 26]. Therefore, these drugs are currently 
used as therapeutic agents in pathologies 
associated with bone degradation from tumor 
origin or not (osteoporosis, multiple myeloma, 
bone metastases and primary bone tumors) 
[27, 28].
Considering that osteolysis promoting tumor 
growth and lung metastasis dissemination are 
the two key points in osteosarcoma progres-
sion, it is tempting to propose ZA and L-mi- 
famurtide combination in osteosarcoma treat-
ment, each of these drugs already proving their 
efficacy. Before clinical application, preclinical 
studies are needed to see whether L-mifa- 
murtide could interfere with ZA induced preven-
tion of associated bone lesions, and conversely 
whether ZA may interfere with L-mifamurtide 




Human KHOS and murine K7M2 osteosarco- 
ma cell lines were purchased from the Ameri- 
can Type Culture Collection (ATCC, LGC Pro- 
mochem, Molsheim, France) and maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, 
Lonza, Switzerland). Murine MOS-J (Jackson 
Laboratory) osteosarcoma cell line was cul-
tured in Roosevelt Park Memorial Institute 
(RPMI) medium (Lonza). Media were supple-
mented with 5% fetal calf serum (Hyclone, 
USA). All cell lines were cultured in a humidified 
5% CO2/air atmosphere at 37°C.
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Drugs
L-mifamurtide was provided by TAKEDA (IDM 
PHARMA SAS). Each vial containing 4 mg of 
mifamurtide powder in 1 g excipient was divid-
ed into 8 tubes and stored at 4°C. Powder was 
reconstituted extemporaneously in sodium ch- 
loride 0.9% and used within 6 hrs. ZA, 1-hydroxy-
2-(1H-imidazole-1-yl) ethylidene-bisphosphonic 
acid supplied as the disodium salt by Novartis 
Pharma AG (Basel, Switzerland), was dissolved 
in PBS as 10 mM stock solution and stored 
at -20°C. Liposome-PBS (clodronateliposome.
com, Netherlands) was used as control.
Cell proliferation
Osteosarcoma cell lines were plated in respec-
tive media and treated with L-mifamurtide or 
zoledronic acid at indicated concentration for 
48 hours, cell growth being measured using 
crystal violet assay as described previously 
[29].
Quantitative reverse transcription-PCR
Total RNA was extracted from mice osteosar-
coma biopsies (24 h after the last drug injec-
tion) using Direct-zol RNA MiniPrep (Zymo Re- 
search) with DNase treatment to remove resid-
ual genomic DNA. RNA quantity and quality was 
evaluated by determining A260/A280 ratio 
using NanoDrop. Complementary DNA was syn-
thesized from isolated RNA using ThermoScript 
real-time polymerase chain reaction (RT-PCR) 
System (Invitrogen, Carlsbad, CA, USA). Qu- 
antitative-PCR (qPCR) was performed using 
primers (Table 1) on Chromo4 instrument (Bi- 
orad, Richmond, CA, USA) using SYBR Green 
Supermix reagents (Biorad). Target gene ex- 
pression was normalized to GAPDH levels in 
respective samples as an internal standard, 
from Janvier Breedings (Le Genest Saint Isle, 
France). Mice were anesthetized by inhalation 
of an isoflurane/air mixture (2%, 1 L/min). 
Primitive osteosarcoma was induced by intra-
muscular paratibial injection of 106 human 
KHOS osteosarcoma cells (xenogeneic model) 
or 3.106 MOS-J or K7M2 mice osteosarcoma 
cells respectively in C57BL/6 and BALB/c mice 
(syngeneic models). Tumor development is 
associated to osteolytic lesions and with dis-
semination of spontaneous lung metastasis 
mimicking the human pathology. The day after 
tumor cell injection, mice were randomly 
assigned (n=8-10) to vehicle (NaCl 0.9%), ZA, 
L-mifamurtide or ZA+L-mifamurtide (bitherapy) 
groups. ZA (100 µg/kg; s.c.) or L-mifamurtide (1 
mg/kg; i.v.) was injected twice per week. Tumor 
volume was measured three times weekly 
(length*width*depth*0.5). Data points were 
expressed as mean tumor volume ± SEM.
Mice were sacrificed when the tumor volume 
reached 10% of body weight for ethical rea-
sons. Primary bone tumor was harvested for 
immunohistochemistry analysis, lung metasta-
ses were macroscopically counted under a bin-
ocular loupe. Animal care and experimental 
protocols were approved by the French Ministry 
of Agriculture (agreement n°D-44015 for the 
Experimental Therapy Unit located at the Me- 
dical School of Nantes) and were realized in 
accordance with the institutional guidelines of 
the regional ethical committee (CREEA Pays 
de la Loire, PdL06, France), with the protocol 
agreement n°1280.01 and 1281.01, and un- 
der the supervision of authorized investiga- 
tors.
Immunohistochemistry
Immunohistochemical stainings were perfor- 
med on formalin-fixed and paraffin-embedded 
Table 1. Primer sequences used in quantitative real-time PCR 
analysis







and the comparative cycle thresh-
old (Ct) method was used to calcu-
late relative quantification of tar- 
get mRNAs. Each assay was per-
formed in triplicate.
Animal models of osteosarcoma
Five week-old female Rj: NMRI 
nude mice for xenogeneic models 
or C57BL/6, BALB/c mice for syn-
geneic models were purchased 
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3 µm sections of tumor samples using ade-
quate primary antibody. Immunodetection per-
formed using secondary biotinylated antibod-
ies and streptavidin HRP-complex was reveal- 
ed with 3,3’-diaminobenyidine (DAB-Dako) fol-
lowed by counterstaining with hematoxylin. 
Negative control was analyzed using a similar 
procedure without primary antibody. Same 
slides were used to estimate the percentage of 
necrosis area among the total tumor.
Micro-CT
Analyses of the bone microarchitecture were 
performed using a SkyScan 1076 in vivo micro-
CT scanner (SkyScan, Kontich, Belgium). Tests 
were performed at early time (d21, tumor vol-
ume around 500 mm3) or at necropsy (tumor 
volume around 2000 mm3). All tibiae/fibulae 
were scanned using the same parameters 
(pixel size 18 µm, 50 kV, 0.5-mm Al filter and 
0.7 degree of rotation step). Three-dimensional 
reconstructions and analysis of bone parame-
ters were performed using NRecon and CTan 
softwares (SkyScan). Calculation of cortical 
bone volume (BV) following 3D morphometric 
parameters (bone ASBMR nomenclature) was 
performed on 5.5-7.2 mm of tibia length 
(depending on mice model) from the fibula 
insertion. This area corresponds to bone in 
close contact with osteosarcoma and excludes 
trabecular bone. Cortical thickness (Ct.Th) was 
defined as the mean cortical volume divided by 
the outer bone surface as previously described 
[30]. Trabecular bone parameters were also 
analyzed.
Statistical analysis
GraphPad InStat v3.02 software (La Jolla, CA, 
USA) was used. In vivo experimentation results 
were analyzed with the unpaired nonparamet-
ric method and Dunn’s multiple comparisons 
following the Kruskal-Wallis test. A p value of 
less than 0.05 was considered statistically 
significant.
Results
L-mifamurtide does not interfere with ZA-
induced bone protection
The first objective of the study was to investi-
gate the potential interference of L-mifamurtide 
treatment with the protective zoledronic acid 
effects on bone during osteosarcoma progres-
sion. Two syngeneic and one xenogeneic mod-
els of osteosarcoma were used: respectively 
K7M2 and MOS-J induced in the BALB/c and 
C57BL/6 mouse strains, and KHOS induced in 
NMRI-nude mice. The day after tumor cell injec-
Figure 1. L-mifamurtide does not interfere with ZA-induced bone protection. A. Representative microCT and 3D 
reconstruction of the tumor-bearing tibia taken ex-vivo, from KHOS xenogeneic (upper panel) and MOS-J syngeneic 
(lower panel) models treated or not (Ctrl) with L-mifamurtide (1 mg/kg), ZA (100 µg/kg), or both (bitherapy) at day 1, 
twice a week, until week 4-5. B. MicroCT quantification of tibia bone volume (BV, mm3) and C. Tibia cortical thickness 
(Co.Th, mm) were calculated on the tibia of tumor bearing mice of the different groups. Median were represented 
for each group (n=4). *p<0.05.
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tion, mice were treated with ZA (100 µg/kg) 
and/or L-mifamurtide (1 mg/kg) twice a week. 
The bone microarchitecture parameters of the 
tumor-bearing tibia have been measured in all 
models and treatment conditions using X-ray, 
micro-CT and 3D reconstruction analysis (Fig- 
ure 1A). Data revealed a decrease of the tumor-
associated osteolysis in the ZA-treated mice as 
compared to the untreated control group. 
Addition of L-mifamurtide did not modulate ZA 
induced bone protection in all models tested 
(Figure 1). An extensive analysis of multiple 
bone parameters revealed an increase of 
tumor-associated bone quality in the ZA treated 
groups as compared to control group. In the 
xenogeneic KHOS mouse model, ZA treatment 
alone and combined with L-mifamurtide in- 
creased the cortical bone volume (BV) (from 
4.88 to 7.79 and 7.62 mm3 respectively as 
compared to control group, p<0.05; Figure 1B), 
the cortical thickness (Co.Th) (from 0.14 to 
0.21 and 0.18 mm; Figure 1C), and trabecular 
parameters (not shown). Similar observations 
were made with the syngeneic mouse model of 
osteosarcoma MOS-J (Figure 1A-C lower panel), 
in which L-mifamurtide treatment did not affect 
the tumor-associated bone preservation as 
compared to control group.
Zoledronic acid does not interfere with L-
mifamurtide-induced inhibition of lung metas-
tasis dissemination and development
The second objective was to investigate the 
effect of L-mifamurtide and ZA on spontaneous 
metastasis dissemination from primary bone 
tumors induced in xenogeneic and syngeneic 
osteosarcoma models. Mice were treated by ZA 
and L-mifamurtide during ~5 weeks (Figure 2A) 
and metastases were counted at equivalent 
Figure 2. Treatment of osteosarcoma bearing mice with L-Mifamurtide alone or in association with ZA inhibits lung 
metastases development in both xenogeneic (KHOS) and syngeneic (MOS-J) models. A. NMRI-nude or C57BL/6 
mice were injected respectively with KHOS (xenogeneic) or MOS-J (syngeneic) osteosarcoma cells and treated with 
vehicle (Ctrl), L-mifamurtide, ZA or both (bitherapy) as described in Figure 1. B. Graphs indicate individual (dots) and 
median (lines) numbers of lung metastases macroscopically counted in mice lungs from each group at equivalent 
primary bone tumor volume (2000 mm3).
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tumor volume. Whatever the model, a trend of 
diminished spontaneous lung metastasis dis-
semination was observed in L-mifamurtide 
treated groups (Figure 2B), and still when ani-
mals were treated with ZA combined with 
L-mifamurtide. No significant differences could 
be observed probably because of the high vari-
ability and the small animal number in each 
group. No difference was observed between 
control and zoledronic acid treated groups.
The combination of ZA and L-mifamurtide 
shows no interference on ZA induced bone pro-
tection effects and L-mifamurtide induced inhi-
bition of lung metastasis development both in 
syngeneic and xenogeneic models of osteosar-
coma in mice. ZA is known to have direct anti-
cancer effects in vitro and in vivo in primary 
and secondary bone tumors [20]. To go further, 
we investigated whether L-mifamurtide would 
affect the antitumor effect of ZA on osteosar-
coma primary bone tumor.
In vivo significant inhibitory effect of L-mi-
famurtide associated with zoledronic acid on 
primary bone tumor progression in syngeneic 
and xenogeneic models of osteosarcoma
The effect of L-mifamurtide and ZA therapeutic 
association was analyzed on primary tumor 
growth in syngeneic (MOS-J) and xenogeneic 
(KHOS) osteosarcoma models. In both cases, 
the tumor cells were injected in close contact 
to the tibia, after periosteum activation. The 
tumors were apparent within 10 days, and 
develop for 4-5 weeks. In each model, L-mi- 
famurtide or ZA alone did not induce any signifi-
cant effect on primary tumor development 
(Figure 3A, B). However, the combination of 
both drugs significantly inhibited tumor growth 
in xenogeneic and syngeneic models. The mean 
tumor size at 22 days for the xenogeneic KHOS 
model was 1285 ± 143 mm3 in the control 
group, compared to 872 ± 128 mm3 in mice 
treated with bitherapy (means ± SEM, p<0.001; 
Figure 3A). The mean tumor size at 35 days for 
the syngeneic MOS-J model was 2284 ± 176 
mm3 in the control group, compared to 1359 ± 
177 mm3 in the group treated with bitherapy 
(means ± SEM, p<0.001; Figure 3B). Similar 
results were obtained in the K7M2 syngeneic 
mice model (not shown). In summary, combina-
tory therapy induced 41% and 55% inhibition of 
mean tumor volume in syngeneic models (MOS-
J and K7M2 respectively) and 37% in the xeno-
geneic model (KHOS) at final time point.
In both syngeneic models, the mean decrease 
in tumor volume of mice treated with ZA and 
Figure 3. L-mifamurtide acts with ZA to reduce tumor growth both in syngeneic (MOS-J) and xenogeneic (KHOS) 
mouse models of osteosarcoma. Mice were treated with L-mifamurtide (1 mg/kg) and ZA (100 µg/kg) or both 
starting at day 1 after tumor cell injection as described in Figure 1. The mean tumor volume from (A) xenogeneic 
KHOS and (B) syngeneic MOS-J mice models, and individual tumor volumes (C) from xenogeneic KHOS model were 
compared between the 4 groups ± SEM (n=8). *p<0.001.
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L-mifamurtide reflects a slowing tumor growth 
in some mice, and no response in others 
(Figure 3C). These unexpected results demon-
strate that L-mifamurtide acts with ZA to reduce 
primary tumor growth in vivo.
L-mifamurtide does not affect osteosarcoma 
cell proliferation in vivo or in vitro
In order to analyze the mechanisms involved in 
the tumor growth inhibition observed in vivo 
with the L-mifamurtide + ZA therapeutic asso-
ciation, the direct effect of each drug alone and 
in combination was studied on osteosarcoma 
cell proliferation in vitro, and in vivo by Ki67 
staining on tumor biopsies. Results show that 
L-mifamurtide alone has no direct effect on the 
proliferation rate of the two osteosarcoma cell 
lines MOS-J and KHOS in vitro (Figure 4A). In 
addition, L-mifamurtide does not significantly 
modify the ZA-induced inhibition of osteosar-
coma cell proliferation (Figure 4A). Considering 
the in vivo mechanisms of action, no significant 
difference could be observed by Ki67 immuno-
histochemical (IHC) staining of KHOS osteosar-
coma in situ cell proliferation between treated 
Figure 4. L-mifamurtide alone or associated with ZA does not directly affect tumor cell proliferation in vivo and in 
vitro. A. Osteosarcoma cells were treated with ZA, L-mifamurtide or both at indicated doses for 48 h. Cell growth was 
determined by crystal violet analysis and compared to control untreated cells. B. KHOS tumor biopsies were col-
lected and Ki67 staining was evaluated by immunohistochemical analysis. Specimens were scored and estimated 
in percentage mean of Ki67+-cells compare to the control group, which corresponds to the mice bearing tumor 
that did not receive any treatment but vehicle. C. Representative picture of Ki67 staining for control and bitherapy 
treated groups.
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and untreated mice (Figure 4B, 4C). Moreover, 
necrosis area percentage is not affected by 
any treatment and similar observations were 
obtained for xenogeneic models (not shown). It 
should be mentioned that osteosarcoma pres-
ents high heterogeneity inter- and intra-groups 
leading to difficult interpretation of IHC results 
at significant level.
Therefore, based on these in vitro results, the 
additive effect of both therapies cannot be 
explained by a direct anti-tumor effect of L- 
mifamurtide.
Mechanisms of action of L-mifamurtide and ZA 
combination in vivo
Because L-mifamurtide is known to activate 
macrophage- and monocyte-based immune 
response, the significant inhibitory effect of 
bitherapy that was observed on primary tumor 
progression may be linked to the modulation of 
these immune cell populations by the associa-
tion of both drugs. Therefore, monocyte/macro-
phage populations were analyzed at primary 
site by the relative proportion of their markers 
at transcript (qPCR) and protein levels (IHC) on 
mouse osteosarcoma biopsies of each group.
IHC analyses showed no differences in the 
macrophages F4/80+ infiltrates in primary bone 
tumors of the different groups in the syngeneic 
MOS-J mouse model (Figure 5A). QPCR analy-
ses from tumor biopsies confirmed that any 
treatment affected the F4/80 (macrophages) 
or CD64 (monocytes/macrophages) mRNA ex- 
pression (Figure 5B). Similar observations were 
made with the KHOS xenogeneic mouse model 
(not shown). Moreover, IHC scoring of iNOS (M1 
macrophages) and ArgI (M2 macrophages) did 
not show any differences between groups (not 
shown). Therefore, Fas mRNA expression was 
evaluated at the primary tumor site in osteo- 
sarcoma models under ZA and L-mifamurti- 
de treatments. Results showed no significant 
modification of Fas mRNA expression in synge-
neic MOS-J (Figure 5B) or xenogeneic KHOS 
(not shown) bone tumor biopsies.
In summary, neither ZA nor L-mifamurtide sig-
nificantly alters the monocyte/macrophage po- 
pulations in the osteosarcoma models used in 
this study. Furthermore, our results suggest 
that L-mifamurtide does not affect macrophage 
activation in the primary tumor site as analyzed 
by iNOS/ArgI IHC staining.
Discussion
The absence of overall survival improvement 
for more than 40 years since the application 
of Rosen poly-chemotherapy protocols [31] is 
Figure 5. L-mifamurtide and/or zoledronic acid treatments did not affect monocyte/macrophage markers in osteo-
sarcoma syngeneic tumor biopsies. A. Staining of osteosarcoma tissues from MOS-J syngeneic mouse model for 
F4/80 22 days after tumor induction. B. Expression of F4/80, CD64, Fas mRNA by MOS-J tumor biopsies. NS: no 
statistic differences between groups. Mean ± SD.
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associated with the lack of relevant therapeutic 
options for high-grade osteosarcoma patients 
(especially patients with lung metastases). In 
addition to conventional chemotherapy, multi-
ple investigational agents have being studied. 
Among them, zoledronic acid has already dem-
onstrated its therapeutic interest for bone 
malignancies including osteosarcoma [19, 20]. 
L-mifamurtide is also one of the more promis-
ing drugs for osteosarcoma acting as immune 
stimulatory agent. At clinical level, Meyer’s 
study was designed to assess whether the 
addition of L-MTP-PE and/or ifosfamide to a 
standard chemotherapeutic regimen (doxorubi-
cin-cisplatin-high dose methotrexate) would 
increase both EFS and overall survival in newly 
diagnosed patients with high-grade osteosar-
coma. ZA is currently proposed in clinical trials 
for osteosarcoma (OS2006 - NCT00470223) 
and Ewing sarcoma (EWING2008 - NCT00- 
987636, EuroEWING2012 - ISRCTN92192408) 
patients, and L-mifamurtide therapy has been 
conducted in phase II (MEMOS - ISRCTN82- 
138287) and phase III trials in patients with 
newly diagnosed OS [18, 32]. Therefore, the 
combination of both drugs could represent a 
promising therapeutic option as both drugs 
target different complementary pathways: L-mi- 
famurtide activates macrophages and mono-
cytes which help to eradicate lung metastasis 
development, and ZA inhibits osteoclast func-
tion by inducing their apoptosis [33], and there-
fore indirectly induced tumor growth inhibition.
In the present study, we described for the first 
time a strong trend for L-mifamurtide to inhibit 
lung metastasis dissemination in both synge-
neic and xenogeneic osteosarcoma models in 
mice. Moreover, its combination with ZA sh- 
owed no interference of both drugs on each 
other. Relevant complementary orthotopic mo- 
dels of osteosarcoma with spontaneous pulmo-
nary metastasis development were used to 
better reproduce the human clinical features 
and to demonstrate the value of this therapeu-
tic approach [34]. Preclinical studies using 
xenogeneic and syngeneic models of osteosar-
coma demonstrated that ZA did not interfere 
with L-mifamurtide-inducing lung metastases 
reduction, and in parallel, L-mifamurtide did 
not modulate the ZA-induced bone protection. 
These results in murine models are in agree-
ment with previous preclinical data reported by 
only one team who described the benefit of 
L-mifamurtide on lung metastasis formation in 
dog models of osteosarcoma [35].
Even if a strong trend (but not significant) 
toward an anti-metastatic activity of L-mifa- 
murtide was shown in our mouse models, we 
could not observe any increase of the overall 
survival in these groups, as it has been previ-
ously described in dogs [35] and patients [18]. 
Overall, analyses of tumor behavior are ren-
dered complicated due to the high tumor het-
erogeneity in osteosarcoma. The general so- 
urce of heterogeneity is caused by specific 
tumor microenvironment, composed of stromal 
cells, the availability of vascular network, and 
the host’s immune system [36]. Primary osteo-
sarcoma progression was so rapid in our mod-
els that pulmonary metastasis dissemination 
was systematically observed, prompting us to 
sacrifice the mice early. In these cases, it could 
not be possible to observe any significant effect 
of L-mifamurtide, but only harm trends. The effi-
cacy of the L-mifamurtide should be investigat-
ed in models with slower metastasis develop- 
ment.
In the second part of our study, we wanted to 
understand why the L-mifamurtide and ZA com-
bination induced a synergistic and significant 
inhibition of primary osteosarcoma progression 
in our mice models whereas each drug showed 
no significant effect. This unexpected result 
was observed both in xenogeneic and synge-
neic models with 32% and 41% inhibition of 
primary tumor growth respectively. Previous 
results from the literature showed a direct and 
indirect anti-tumor activity of L-mifamurtide on 
osteosarcoma cells in vitro or in metastases 
development after resection of the primary 
tumor [8, 37]. Moreover, this inhibitory effect 
on primary tumor growth is even more unex-
pected as ZA and L-mifamurtide were not asso-
ciated with conventional chemotherapy as usu-
ally in clinics. Several hypotheses could be 
proposed to explain those results.
First, both drugs act synergistically by directly 
inhibiting tumor proliferation. However, when 
we studied the potential direct anti-tumor activ-
ity of L-mifamurtide alone and associated with 
ZA in vitro, no inhibition of osteosarcoma cell 
growth could be observed. In addition, tumor 
biopsies were collected in mice for histological 
analysis 24 hours after treatment at early 
(week 3) or end time point (week 5). We were 
unable to show a decreased proliferation rate 
as analyzed by Ki67 staining in the bitherapy 
group in our different models. However, we may 
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wonder whether the effects of ZA and L-mi- 
famurtide are transient as a consequence of 
fever and pro-inflammatory cytokines up regu-
lation for example. In that case, these parame-
ters have to be analyzed earlier. In fact, the syn-
ergic interaction of ZA and L-mifamurtide on 
tumor progression may be due to a transient 
but sufficient effect on pro-inflammatory cyto-
kine upregulation.
Various studies have reported the stimulation 
of macrophages by L-mifamurtide + IFN-γ in 
vitro [38, 39]. ‘Priming’ of macrophages by 
IFN-γ may enhance liposome up-take and im- 
prove the response to bacterial components 
such as MDP or presumably mifamurtide. We 
therefore hypothesized that ZA treatment may 
increase the IFN-γ level at plasma or local loca-
tion high enough to ‘prime’ macrophages. It has 
been reported by clinicians that zoledronic acid 
therapy leads to fever symptoms in patients for 
24-48 h, probably due to transient TNF-α and 
IL-6 increases, but not IFN-γ [40]. We indeed 
confirm these data, as we were unable to show 
a detectable IFN-γ plasma level in the mice 24 
hours after zoledronic acid treatment (not 
shown). It is known that L-mifamurtide binds 
to the cytosolic NOD2 “receptor” to stimulate 
NF-ĸB signaling pathways, activating the ex- 
pression of inflammatory cytokines including 
IL-12 [41]. It is admitted that plasma IL-12 
increases after administration of L-mifamurtide, 
and that IL-12 upregulates FAS expression in 
human osteosarcoma lung metastases. It also 
known that Fas expression inversely correlates 
with metastatic activity in osteosarcoma [42]. 
However, we were unable to observe any en- 
hancement of Fas mRNA expression (follow- 
ing L-mifamurtide treatment) in primary bone 
tumor in both xenogeneic and syngeneic mouse 
models of osteosarcoma (not shown).
Because L-mifamurtide acts as a potent stimu-
lator of macrophage activity preferentially at 
lung site [43], the question raised about its 
action at the primary osteosarcoma site. In par-
allel, the role of ZA in tumor macrophages pop-
ulation is controversial. Because ZA induced 
osteoclast apoptosis (via the inhibition of the 
small G protein prenylation), it could be sug-
gested that ZA also affects macrophages, as 
previously described in breast cancer [44], 
especially those present in the bone tumor 
microenvironment. We hypothesize that L-mi- 
famurtide may counterbalance the potential 
side effect of ZA on TAMs. Different approach-
es by IHC, qPCR and flow cytometry were used 
to study macrophage sub-populations in mice 
tumor biopsies from xenogeneic and syngeneic 
osteosarcoma models. However, no differenc-
es in macrophage sub-populations infiltrating 
primary bone tumor could be observed what-
ever the methodological approaches used.
In conclusion, no interference between zole-
dronic acid and the liposomal form of mifamur-
tide was observed for the studied parameters. 
Combination of both drugs showed no signifi-
cant difference on ZA induced bone protection 
effects and on L-mifamurtide induced inhibition 
of lung metastasis development. Unexpectedly, 
an additive and in some cases synergistic inhib-
itory effect was observed on primary osteosar-
coma progression that could not be explained 
by a direct synergy between drugs on osteosar-
coma cell proliferation, neither by a modifica-
tion of TAMs population at the primary bone 
site. Even if the mechanism remains unclear up 
to now, those results constitutes a promising 
demonstration for clinical application in osteo-
sarcoma patients.
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